Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Chronic lower back pain (CLBP) is a long-lasting musculoskeletal condition characterized by persistent pain in the lower spine lasting more than 12 weeks. According to Yao-kan Zhang et al., 2025, low back pain affects over 600 million people globally and remains the leading cause of disability worldwide. Current therapies include NSAIDs, opioids, muscle relaxants, antidepressants, and interventional pain management approaches. According to the chronic lower back pain pipeline analysis by Expert Market Research, the drug pipeline is increasingly focused on non-opioid analgesics, regenerative therapies, and novel biologics. Rising disease burden, unmet clinical needs, and advances in pain neuroscience are expected to drive steady pipeline growth in the coming years.
-
Major companies involved in the chronic lower back pain pipeline analysis include Vertanical GmbH, Creative Medical Technology Holdings Inc., and others.
-
Leading drugs currently in the pipeline include VER-01, CELZ-201-DDT, PIPE-791, and others.
-
The pipeline growth is driven by rising chronic pain prevalence, increasing focus on non-opioid therapies, and advancing biologics and regenerative candidates addressing long-term pain control and improved patient safety.
Report Coverage
The Chronic Lower Back Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic lower back pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic lower back pain. The chronic lower back pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic lower back pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic lower back pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic lower back pain.
Read more about this report - Request a Free Sample
Chronic Lower Back Pain Pipeline Outlook
Chronic lower back pain is a long-lasting musculoskeletal condition characterized by pain persisting for more than twelve weeks in the lumbar region. It develops from disc degeneration, facet joint disease, muscle strain, nerve compression, or inflammatory and infectious changes, often evolving from an acute episode into persistent structural, neurological, or biological dysfunction affecting mobility and quality of life.
Chronic lower back pain treatment is managed with non-steroidal anti-inflammatory drugs, muscle relaxants, physical therapy, minimally invasive interventions, and emerging non-opioid therapies, based on disease cause and symptom severity. In March 2025, Persica Pharmaceuticals reported positive Phase Ib results for PP353, a non-opioid intradiscal antibiotic therapy. The treatment demonstrated statistically meaningful and durable pain reduction in chronic lower back pain patients with Modic type 1 changes by targeting disc-space infection and inflammation.
Chronic Lower Back Pain Epidemiology
Chronic lower back pain underscores the significant unmet need driven by high global prevalence. According to Yao-kan Zhang et al., 2025, over 600 million individuals worldwide were affected, making it the leading cause of disability. Prevalence rates remain consistently higher in females than males, with an age-standardized prevalence rate of 10,743 per 100,000 females versus 6,528 per 100,000 males in 2021. South Asia and East Asia account for the highest prevalence burden globally, reinforcing strong demand for innovative and targeted therapies within the drug pipeline.
Chronic Lower Back Pain – Pipeline Therapeutic Assessment
This section of the report covers the analysis of chronic lower back pain drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The chronic lower back pain pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Chronic Lower Back Pain Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 37%, covers a major share of the total chronic lower back pain clinical trials, driven by strong proof-of-concept data and rising investment in non-opioid therapies. Phase III accounts for 24%, reflecting advancing clinical validation. This distribution highlights sustained innovation, collectively strengthening the chronic lower back pain market.
Chronic Lower Back Pain Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the chronic lower back pain pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The chronic lower back pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic lower back pain. Metabolic hormone–based therapies are emerging in the chronic lower back pain drug pipeline to address pain linked with obesity. For instance, retatrutide (LY3437943), a triple glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonist, is under Phase III evaluation for reducing chronic low back pain severity in overweight and obese adults by improving metabolic and inflammatory pathways.
Chronic Lower Back Pain Clinical Trials – Key Players
The EMR report for the chronic lower back pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic lower back pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic lower back pain clinical trials:
- Vertanical GmbH
- Creative Medical Technology Holdings Inc.
- Contineum Therapeutics
- Centrexion Therapeutics
- Eli Lilly and Company
- Kolon TissueGene, Inc.
- Mesoblast, Ltd.
- Skye Biologics Holdings, LLC
- Euraxi Pharma
Chronic Lower Back Pain – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic lower back pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic lower back pain drug candidates.
Drug: VER-01
VER-01 is a full-spectrum cannabis extract being sponsored by Vertanical GmbH for the treatment of chronic low back pain. This Phase 3 study is examining the efficacy and safety of VER-01 compared to placebo in patients with inadequate response to non-opioid analgesics. VER-01 acts through the endocannabinoid system, primarily targeting CB1 and CB2 receptors to modulate pain signaling and inflammation. The drug is being administered orally as an oil-based formulation. The trial is enrolling approximately 700 patients and is evaluating pain reduction, functional improvement, and safety outcomes.
Drug: CELZ-201-DDT
CELZ-201-DDT is a proprietary regenerative stem cell-based therapy sponsored by Creative Medical Technology Holdings Inc. for chronic lower back pain associated with degenerative disc disease. The Phase 1/2a ADAPT study is currently recruiting and is evaluating safety, tolerability, and preliminary effectiveness. This study is examining paraspinal intramuscular administration of CELZ-201-DDT, delivered via ultrasound-guided injections into lumbar musculature. The drug works by promoting tissue repair, disc remodeling, and improved local blood supply. The intramuscular route of administration aims to provide a minimally invasive, non-surgical therapeutic option for sustained pain reduction.
Drug: PIPE-791
PIPE-791 is a novel, brain-penetrant small-molecule LPA1 receptor antagonist being developed by Contineum Therapeutics for chronic low back pain. The Phase 1b study is actively evaluating safety, tolerability, and preliminary analgesic efficacy. This trial examines whether oral PIPE-791 modulates lysophosphatidic acid signaling involved in pain sensitization and neuroinflammation. The study enrolls adults with chronic low back pain, with or without radiculopathy, using a randomized, double-blind, placebo-controlled crossover design. Daily oral dosing is being administered to assess pain reduction, pharmacodynamic response, and overall tolerability.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Chronic Lower Back Pain Pipeline Insight Report
- Which companies/institutions are leading the chronic lower back pain drug development?
- Which company is leading the chronic lower back pain pipeline development activities?
- What is the current chronic lower back pain commercial assessment?
- What are the opportunities and challenges present in the chronic lower back pain pipeline landscape?
- What is the efficacy and safety profile of chronic lower back pain pipeline drugs?
- Which company is conducting major trials for chronic lower back pain drugs?
- Which companies/institutions are involved in chronic lower back pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in chronic lower back pain?
Reasons To Buy This Report
The Chronic Lower Back Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic lower back pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic lower back pain collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share